(Image source: businesswire.com) Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) shares are advancing this morning on news that the FDA has granted the biopharmaceutical company accelerated approval for the drug Northera, which treats dizziness, fatigue, blurry vision, and a host of other symptoms caused by the NOH disease ( symptomatic neurogenic orthostatic hypotension). People who suffer from the disease have a hard time maintaining blood pressure levels when they stand up. The disorder affects an estimated 80,000 to 150,000 Americans. According to RTTNews.com, Northera is first new treatment alternative for the disease that will be available to patients in nearly two decades.